CR9074A - Agente para la profilaxis o tratamiento del sindrome metabolico - Google Patents

Agente para la profilaxis o tratamiento del sindrome metabolico

Info

Publication number
CR9074A
CR9074A CR9074A CR9074A CR9074A CR 9074 A CR9074 A CR 9074A CR 9074 A CR9074 A CR 9074A CR 9074 A CR9074 A CR 9074A CR 9074 A CR9074 A CR 9074A
Authority
CR
Costa Rica
Prior art keywords
prophylaxis
agent
treatment
metabolic syndrome
salt
Prior art date
Application number
CR9074A
Other languages
English (en)
Inventor
Nishigaki Nobuhiro
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35517142&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR9074(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of CR9074A publication Critical patent/CR9074A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Abstract

La presente invencion provee un agente para la profilaxis o tratamiento del sindrome metabolico, que comprende acido 2-etoxi-1-[[2'-(5-oxo-2,5-dihidro-1, 2,4-oxadiazol-3-il)bifenil-4-ilhnetilj-1H-bencimidazol-7- carboxilico o una sal del mismo o un profarmaco del mismo y una sustancia tipo agonista de PPARy combinados.
CR9074A 2004-10-07 2007-04-20 Agente para la profilaxis o tratamiento del sindrome metabolico CR9074A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004294889 2004-10-07
JP2005125373 2005-04-22

Publications (1)

Publication Number Publication Date
CR9074A true CR9074A (es) 2007-08-28

Family

ID=35517142

Family Applications (1)

Application Number Title Priority Date Filing Date
CR9074A CR9074A (es) 2004-10-07 2007-04-20 Agente para la profilaxis o tratamiento del sindrome metabolico

Country Status (17)

Country Link
US (1) US20070270477A1 (es)
EP (1) EP1799203A1 (es)
JP (1) JP2008515767A (es)
KR (1) KR20070073872A (es)
AR (1) AR052015A1 (es)
AU (1) AU2005290394A1 (es)
BR (1) BRPI0516246A (es)
CA (1) CA2583768A1 (es)
CR (1) CR9074A (es)
IL (1) IL182055A0 (es)
MX (1) MX2007003716A (es)
NO (1) NO20071889L (es)
PE (1) PE20060971A1 (es)
RU (1) RU2007116969A (es)
TW (1) TW200616625A (es)
UY (1) UY29155A1 (es)
WO (1) WO2006038722A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2007001195A1 (es) * 2006-04-27 2008-01-04 Takeda Pharmaceutical Composicion farmaceutica solida que comprende un nucleo con un compuesto derivado de bencimidazol y una grasa o aceite, una primera capa que comprende un polimero de alto peso molecular que recubre el nucleo y una segunda capa que comprende pioglitazona, util para tratar enfermedades circulatorias.
JP2008195625A (ja) * 2007-02-08 2008-08-28 Pharma Frontier Kk Ｇ蛋白質共役型レセプター抑制剤および医薬
JP2013512199A (ja) * 2009-11-30 2013-04-11 ジエンス ハンセン ファーマセウティカル カンパニー リミテッド アジルサルタン有機アミン塩、その製造方法及び使用
WO2012012156A1 (en) * 2010-07-21 2012-01-26 Myomics, Inc. Methods and compositions for the improvement of skeletal muscle function in a mammal
JP5981940B2 (ja) * 2011-01-20 2016-08-31 ジエンス ハンセン ファーマセウティカル カンパニー リミテッド アジルサルタン有機アミン塩、その製造方法及び使用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL102183A (en) * 1991-06-27 1999-11-30 Takeda Chemical Industries Ltd The heterocyclic compounds are converted into biphenyl groups, their production and the pharmaceutical compositions containing them
ES2175385T5 (es) * 1996-04-05 2006-06-01 Takeda Chemical Industries, Ltd. Combinacion farmaceutica que contiene un compuesto que tiene actividad antagonista de angiotensina ii y un compuesto que aumenta la sensibilidad a la insulina.
BR9908474A (pt) * 1998-03-04 2000-12-05 Takeda Chemical Industries Ltd Preparação de liberação prolongada, processo para a produção de uma preparação de liberação prolongada, e, composição farmacêutica
AR033390A1 (es) * 2000-08-22 2003-12-17 Novartis Ag Una composicion farmaceutica que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina, el uso de dicha composicion para la fabricacion de un medicamento y un kit de partes
WO2002015935A1 (fr) * 2000-08-25 2002-02-28 Takeda Chemical Industries, Ltd. Agents de reduction du fibrinogene
JP4484427B2 (ja) * 2001-12-03 2010-06-16 武田薬品工業株式会社 インスリン抵抗性改善剤
US20050032854A1 (en) * 2001-12-03 2005-02-10 Kiminori Kawahara Insulin resistance improving agents
US7232828B2 (en) * 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
WO2004017896A2 (en) * 2002-08-21 2004-03-04 Merck & Co., Inc. Combination therapy using a dual ppar alpha/gamma agonist and an angiotensin ii type i receptor antagonist
CN100438911C (zh) * 2002-12-27 2008-12-03 武田药品工业株式会社 体重增加抑制剂

Also Published As

Publication number Publication date
BRPI0516246A (pt) 2008-08-26
US20070270477A1 (en) 2007-11-22
AR052015A1 (es) 2007-02-28
UY29155A1 (es) 2006-02-24
PE20060971A1 (es) 2006-11-15
EP1799203A1 (en) 2007-06-27
WO2006038722A1 (en) 2006-04-13
AU2005290394A1 (en) 2006-04-13
CA2583768A1 (en) 2006-04-13
RU2007116969A (ru) 2008-11-20
JP2008515767A (ja) 2008-05-15
TW200616625A (en) 2006-06-01
NO20071889L (no) 2007-06-26
KR20070073872A (ko) 2007-07-10
IL182055A0 (en) 2007-07-24
MX2007003716A (es) 2007-04-23

Similar Documents

Publication Publication Date Title
GT200900283A (es) "terapia de combinación con un compuesto actuando como un inhibidor del receptor adp plaquetario".
GT200500158A (es) Derivados de amino-5,5-difenilimidazolona para la inhibicion de la b-secretasa
CY1118179T1 (el) Φαρμακευτικη συνθεση
AR051099A1 (es) Combinaciones terapeuticas que comprenden inhibidor de poli(adp-ribosa)polimerasas
ECSP066990A (es) Formulaciones con liberación controlada de principio activo que contienen vardenafilo
GT200600163A (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de la depresion
CL2007003520A1 (es) Compuestos derivados de heterociclos sustituidos con morfolina, inhibidores de la actividad pi3 quinasa; composicion farmaceutica que comprende a dichos compuestos; kit farmaceutico; y su uso para el tratamiento profilactico o terapeutico del cancer.
PA8637201A1 (es) Difenilimidazopirimidina e-imidazol aminas como inhibidores de la b-secretasa
CL2011000101A1 (es) Compuestos derivados de piridazina sustituida; inhibidores de la señalizacion hedgehog y smo; composicion farmaceutica; y uso para el tratamiento de trastornos o sindromes asociados con enfermedades hiperproliferativas.
AR064725A1 (es) Profilaxis y tratamiento del complejo respiratorio porcino (prdc). uso
CL2007001427A1 (es) Sal de maleato de 5-amino-3-(2',3'-di-o-acetil-beta-d-ribofuranosil)-3h-tiazolo[4,5-d]pirimidin-2-ona; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de una infeccion po
DOP2009000165A (es) Derivados de oxindol sustituido, medicamentos que los comprenden y uso de los mismos
ECSP099778A (es) Dosis intravenosa y oral de un inhibidor p2y12 de acción directa y reversible
CR20120171A (es) Uso de n-(4-((3-(2-amino-4-pirimidinil)-2-piridinil)oxi) fenil)-4-(4-metil-2-tienil)-1-ftalazinamina en el tratamiento de cáncer resistente al agente antimitótico
MX2010005012A (es) Composiciones para el tratamieno y prevencion de inflamacion de los parpados que comprenden un ingrediente osmoticamente activo y un vasocosntrictor.
AR061446A1 (es) Utilizacion de la 1,7 -dimetilxantina para la fabricacion de un medicamento psicoanaleptico no ansiogeno destinado al tratamiento de un trastorno neuropsiquiatrico
CL2011000806A1 (es) Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion del ictus en pacientes que padecen fibrilacion auricular.
ATE392889T1 (de) Orale antimikrobielle pharmazeutische zusammensetzungen
CO6321285A2 (es) Uso de 3,11b-cis- dihidrotetrabenazina en el tratamiento de la esclerosis multiple y la mielitis autoinmunitaria
CR9074A (es) Agente para la profilaxis o tratamiento del sindrome metabolico
MX2008002456A (es) Uso de ambroxol para el tratamiento de infecciones por rinovirus.
BRPI0608287A2 (pt) agente endoparasiticida
AR072951A1 (es) Uso de dronedarona o una sal aceptable farmaceuticamente de esta, para la preparacion de un medicamento para regular el nivel de potasio en la sangre
BRPI0712561B8 (pt) Uso de 3-oxo-3,4-diidro-2-pirazinacarboxamida
DE502006007693D1 (de) Pelletförmige reatrdzubereitung enthaltend cinnarizin und dimenhydrinat gegen schwindel

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)